Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • NeuroSciences Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Saudi Medical Journal
  • Other Publications
    • NeuroSciences Journal
  • My alerts
  • Log in
Saudi Medical Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
CorrespondenceCorrespondence
Open Access

Comments on: Dermatomyositis and Kaposi sarcoma

Ali S. Jawad
Saudi Medical Journal June 2021, 42 (6) 704; DOI: https://doi.org/10.15537/smj.2021.42.6.704
Ali S. Jawad
Department of Rheumatology Royal London Hospital London, United Kingdom https://orcid.org/0000-0002-0434-7488
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

To the Editor

Alghanim and Gasmelseed postulate that dermatomyositis (DM) in the patient who later developed Kaposi’s sarcoma (KS) was a paraneoplastic syndrome.1 We do not agree with their hypothesis.

Paraneoplastic syndromes are rare disorders that develop when T lymphocytes directed against antigens common to the tumor and normal cells attack normal tissues. The patient reported had lymphopenia prior to treatment. Furthermore, the patient developed KS one month after the diagnosis of DM and receiving one gram a day of methylprednisolone intravenously for 3 days, followed by 60-mg oral prednisolone daily. This treatment is enough to cause significant immunosuppression, weakening the immunological surveillance, allowing the reactivation of the latent human herpesvirus 8 infection. As a result, there is proliferation of the infected endothelial cells and the development of KS. One dose of 1 gm of methylprednisolone leads to selective T lymphocyte suppression 2 hours after each infusion, which is maximal at 6 hours with complete recovery 24 hour after each dose.2 However, the 3 pulses of methylprednisolone were followed by daily doses of 60mg prednisolone, a large dose, thus maintaining the T lymphocyte suppression. The azathioprine has a lower onset of action and therefore its contribution is minimal in this patient.

There are many reports of patients developing KS after immunosuppressive therapy for DM and polymyositis but the interval in the current patient is one month which is the shortest but never the less, he has received intensive immunosuppression, has had pretreatment lymphopenia and is 73-years-old, older than the other patients reported.3-7

Kaposi’s sarcoma should be considered in patients on immunosuppression if they develop a new rash.

Reply from the Author

No reply was received from the Author.

  • Copyright: © Saudi Medical Journal

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

  1. 1.↵
    1. Alghanim KK,
    2. Gasmelseed BG.
    Kaposi’s sarcoma associated with adult dermatomyositis. Saudi Med J 2021; 42: 570–573.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Fan PT,
    2. Yu DT,
    3. Clements PJ,
    4. Fowlston S,
    5. Eisman J,
    6. Bluestone R.
    Effect of corticosteroids on the human immune response: comparison of one and three daily 1 gm intravenous pulses of methylprednisolone. J Lab Clin Med 1978; 91: 625.
    OpenUrlPubMed
  3. 3.↵
    1. Dantzig PI.
    Kaposi Sarcoma and Polymyositis. Arch Dermatol 1974; 110: 605–607.
    OpenUrlCrossRefPubMed
  4. 4.
    1. Weiss VC,
    2. Serushan M.
    Kaposi’s sarcoma in a patient with dermatomyositis receiving immunosuppressive therapy. Arch Dermatol 1982; 118: 183–185.
    OpenUrlCrossRefPubMed
  5. 5.
    1. Almog Y,
    2. Ben-Yehuda A,
    3. Ben-Chetrit E.
    Dermatomyositis associated with the recurrence of transitional cell carcinomas and Kaposi’s sarcoma. Clinical and Experimental Rheumatology 1991; 9: 285–288.
    OpenUrlPubMed
  6. 6.
    1. Simeoni, S.,
    2. Puccetti, A.,
    3. Moruzzi, S. et al.
    Dermatomyositis complicated with Kaposi sarcoma: a case report. Clin Rheumatol 2007; 26: 440–442.
    OpenUrlPubMed
  7. 7.↵
    1. Liu Y,
    2. Jiang L.
    Cutaneous Kaposi’s sarcoma. BMJ 2021; 373: n926.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Saudi Medical Journal: 42 (6)
Saudi Medical Journal
Vol. 42, Issue 6
1 Jun 2021
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Saudi Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comments on: Dermatomyositis and Kaposi sarcoma
(Your Name) has sent you a message from Saudi Medical Journal
(Your Name) thought you would like to see the Saudi Medical Journal web site.
Citation Tools
Comments on: Dermatomyositis and Kaposi sarcoma
Ali S. Jawad
Saudi Medical Journal Jun 2021, 42 (6) 704; DOI: 10.15537/smj.2021.42.6.704

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comments on: Dermatomyositis and Kaposi sarcoma
Ali S. Jawad
Saudi Medical Journal Jun 2021, 42 (6) 704; DOI: 10.15537/smj.2021.42.6.704
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • To the Editor
    • References
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Management of trigger finger (stenosing tenosynovitis)
  • Comment on: Post surgical hypoparathyroidism
  • Overcoming socioeconomic obstacles is important in achieving equity in health care
Show more Correspondence

Similar Articles

CONTENT

  • home

JOURNAL

  • home

AUTHORS

  • home
Saudi Medical Journal

© 2025 Saudi Medical Journal Saudi Medical Journal is copyright under the Berne Convention and the International Copyright Convention.  Saudi Medical Journal is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3175. Print ISSN 0379-5284.

Powered by HighWire